A case of Li-Fraumeni syndrome diagnosed with bilateral breast cancer in the initial high-risk surveillance in a family which multi-gene panel testing was effective

DOI
  • Haruyama Yurie
    Breast Oncology Center, Cancer Institute Hospital of Japan Foundation for Cancer Research
  • Nakashima Eri
    Breast Oncology Center, Cancer Institute Hospital of Japan Foundation for Cancer Research
  • Inari Hitoshi
    Breast Oncology Center, Cancer Institute Hospital of Japan Foundation for Cancer Research
  • Maeda Tetsuyo
    Breast Oncology Center, Cancer Institute Hospital of Japan Foundation for Cancer Research
  • Nishimura Meiko
    Breast Oncology Center, Cancer Institute Hospital of Japan Foundation for Cancer Research
  • Habano Eri
    Department of Clinical Genetics, Cancer Institute Hospital of Japan Foundation for Cancer Research
  • Arakawa Hiromi
    Department of Clinical Genetics, Cancer Institute Hospital of Japan Foundation for Cancer Research
  • Kaneko Keika
    Department of Clinical Genetics, Cancer Institute Hospital of Japan Foundation for Cancer Research
  • Kokubu Yumi
    Department of Diagnosis Imaging Center, Cancer Institute Hospital of Japan Foundation for Cancer Research
  • Osako Tomo
    Division of Pathology, Cancer Institute Hospital of Japan Foundation for Cancer Research
  • Ueki Arisa
    Department of Clinical Genetics, Cancer Institute Hospital of Japan Foundation for Cancer Research
  • Ueno Takayuki
    Breast Oncology Center, Cancer Institute Hospital of Japan Foundation for Cancer Research
  • Ohno Shinji
    Breast Oncology Center, Cancer Institute Hospital of Japan Foundation for Cancer Research Department of Breast&Thyroid Surgery, Sagara Hospital

Bibliographic Information

Other Title
  • 多遺伝子パネル検査で診断に至ったLi-Fraumeni症候群の未発症血縁者：初回の乳房ハイリスクサーベイランスで両側乳癌の診断に至った1例
Published
2024-10-25
DOI
  • 10.18976/jsht.24.2_153
Publisher
The Japanese Society for Hereditary Tumors

Search this article

Description

<p>　Li-Fraumeni syndrome (LFS) is a highly penetrant cancer syndrome associated with a germline pathogenic variant of TP53, which is responsible to develop premenopausal breast cancers. According to the NCCN guideline version 2 2024 for female LFS carriers, it is recommended to take annual breast MRI and mammography. It is also considered an option to undergo bilateral risk-reducing mastectomy with genetic counseling. LFS has been mostly diagnosed by single-gene testing among patients; who were estimated high risk according to the classic criteria of LFS or Chompret criteria. However, since multi-gene panel testing has recently become more common in some countries such as the United States, it has been revealed that there are some cases of LFS with different clinical features from conventional LFS. We present a case of LFS whose relative was diagnosed with LFS by a multi-gene panel test, and who had bilateral breast cancer which were diagnosed in the first breast surveillance. We have experienced 5 cases of LFS with breast cancer in our hospital. In order to clarify the clinicopathological characteristics of breast cancer in LFS, we examined the concordance between clinicopathological factors and diagnostic criteria in the five cases.</p>

Journal

Keywords

Details 詳細情報について

Report a problem

Back to top